Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Sep
08
Today In Oncology
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo